GlassScriptPhysician profile
Kurt T Flinders
NPI 1780830612
$5,875.91
in general payments reported to CMS, 2019-2025
52 companies · $1,028 in 2025
The $1,028 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $380 · 2020: $777 · 2021: $940 · 2022: $1,094 · 2023: $842 · 2024: $816 · 2025: $1,028.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,685.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,004.87 | 2020-2025 | |
| Glaxosmithkline, LLC. | $498.77 | 2019-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Lilly USA, LLC | $477.99 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $413.23 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Janssen Pharmaceuticals, INC | $351.90 | 2019-2023 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $282.55 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Pfizer INC. | $268.44 | 2020-2025 | |
| Astellas Pharma US INC | $259.71 | 2019-2025 | Veozah |
| Amgen INC. | $249.03 | 2020-2025 | Evenity, Prolia |
| Abbott Laboratories | $170.39 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Axsome Therapeutics, INC. | $128.43 | 2023-2025 | Auvelity, Sunosi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $122.53 | 2022-2025 | Caplyta |
| Novo Nordisk INC | $115.95 | 2019-2025 | Wegovy |
| Biohaven Pharmaceutical Holding Company LTD. | $110.74 | 2022 | |
| Dynavax Technologies Corporation | $98.13 | 2022-2025 | Heplisav-B |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kurt Flinders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.